| Course | NUR 635 Advanced Pharmacology |
|---|---|
| Topic | Topic 8 |
| Paper type | Comprehensive prescribing case |
| Length | About 1,140 words, 3 pages |
| Format | APA 7 student paper |
| School | Grand Canyon University (GCU) |
| Program | MSN |
| Updated | October 2026 |
Free sample paper for NUR 635 Topic 8
Symptoms That Now Start at 2 p.m.: A Comprehensive Prescribing Case for Dopaminergic Augmentation of Restless Legs Syndrome in a 62-Year-Old Man
[Author Name]
College of Nursing and Health Care Professions, Grand Canyon University
NUR-635: Advanced Pharmacology
Topic 8 Benchmark Assignment
[Instructor Name]
March 4, 2030
The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.
Symptoms That Now Start at 2 p.m.: A Comprehensive Prescribing Case for Dopaminergic Augmentation of Restless Legs Syndrome in a 62-Year-Old Man
The Patient in Full
Mr. O., a composite 62-year-old accountant weighing 88 kg, has had restless legs syndrome for nine years. Pramipexole was started three years ago at 0.125 mg each evening and has been increased three times to 0.75 mg at 7 p.m. His symptoms, an urge to move the legs with crawling sensations that ease with walking, used to begin around 10 p.m.; they now begin around 2 p.m., are more intense and have spread to his arms. His International Restless Legs Syndrome Study Group rating scale score is 29 of 40, in the severe range. Other medications: sertraline 100 mg daily for depression, well controlled, and diphenhydramine 50 mg at night, bought without a prescription, for sleep. He drinks two beers most evenings. His wife reports loud snoring. Laboratory results: ferritin 48 ng/mL, transferrin saturation 17 percent, hemoglobin 13.9 g/dL, creatinine 1.0 mg/dL, estimated creatinine clearance by Cockcroft-Gault about 95 mL/min, phosphate normal.
The Therapeutic Goal
Success means symptoms that begin no earlier than 9 p.m., do not involve his arms and are rated below 15 on the rating scale, a reduction of at least half, within 16 weeks, with pramipexole stopped. A secondary goal is uninterrupted sleep on at least five nights a week.
Selecting the Agents, With Alternatives Declined
The earlier onset, spread to the arms and escalating dose describe dopaminergic augmentation, a worsening of restless legs syndrome caused by its treatment, and the defining implication is that the usual response, another increase in pramipexole, is exactly the wrong one. Augmentation is the main reason dopamine agonists are no longer favored for long-term treatment, and current guidance on managing it advises correcting iron deficiency, adding or switching to an alpha-2-delta ligand, and tapering the agonist (Garcia-Borreguero et al., 2016).
The plan has three parts. First, iron: his ferritin is 48 ng/mL and transferrin saturation 17 percent, both below the thresholds at which supplementation is advised for restless legs syndrome, ferritin 75 ng/mL or less or saturation below 20 percent (Winkelman et al., 2025), and intravenous ferric carboxymaltose carries a strong recommendation. Oral ferrous sulfate was considered and declined as the first step because it raises brain iron slowly, is often poorly tolerated and has only a conditional recommendation. Second, pregabalin, an alpha-2-delta ligand with a strong recommendation, which does not cause augmentation. Gabapentin enacarbil was equally supported but declined because his insurance does not cover it; gabapentin was declined because its absorption is less predictable at higher doses. Third, a slow taper of pramipexole. Switching to the rotigotine patch was declined because it is still a dopamine agonist, and opioids, conditionally recommended, are reserved for failure of these steps.
Two exacerbating factors are addressed before any new drug is added: diphenhydramine, a sedating antihistamine that worsens restless legs symptoms, stops, and he will aim to limit alcohol to two drinks a week. Sertraline can also worsen symptoms. Changing it was discussed; because his depression is well controlled and he preferred not to change, it continues, with the option of revisiting it if symptoms persist.
Dose, Route and Interval
Ferric carboxymaltose 750 mg intravenously, two infusions one week apart, the labeled regimen for adults weighing 50 kg or more, given in the infusion clinic. Intravenous iron is chosen for speed: brain iron is thought to be central to the disorder, and intravenous dosing raises stores in weeks rather than months.
Pregabalin 75 mg by mouth at 5 p.m., about two hours before his original symptom time, increased to 150 mg after one week and to 225 mg or 300 mg at two-week intervals if needed. No renal adjustment is required at his clearance of 95 mL/min; the dose would be reduced if clearance fell below 60 mL/min.
Pramipexole is tapered only after pregabalin reaches an effective dose, by 0.125 mg every one to two weeks, from 0.75 mg to zero over about 6 to 12 weeks. He was warned that symptoms often worsen for one to two weeks after the last dose before they settle.
Interactions Across the Whole List, and Monitoring
Pregabalin with alcohol and with diphenhydramine adds sedation and dizziness, which is one more reason both are reduced or stopped. Pregabalin with any future opioid would add respiratory depression, particularly if he has untreated obstructive sleep apnea, and his snoring has prompted referral for a sleep study. Pregabalin has no pharmacokinetic interaction with sertraline or pramipexole. Ferric carboxymaltose commonly lowers serum phosphate: in two randomized trials, about three quarters of patients given ferric carboxymaltose developed hypophosphatemia, compared with fewer than 1 in 10 given iron derisomaltose (Wolf et al., 2020).
Monitoring, with thresholds: phosphate two weeks after the second infusion, with oral phosphate and a review of the plan if it falls below 2.0 mg/dL; ferritin and transferrin saturation 8 to 12 weeks after the infusions, repeating iron if ferritin remains at or below 100 ng/mL or saturation below 20 percent; the rating scale every four weeks, with failure to fall by at least 6 points after eight weeks on pregabalin 300 mg prompting a review of the plan; dizziness, daytime sleepiness, weight gain above 3 kg or ankle swelling at each visit; and mood, since both pramipexole withdrawal and pregabalin can affect it.
Teaching and Counseling
Mr. O. was told that the medicine he has been taking has, over time, made the condition worse and that this is a known, reversible effect; that the next month may be uncomfortable while pramipexole is reduced; to take pregabalin at 5 p.m., not at bedtime, so that it is working when symptoms begin; not to drive if he feels dizzy or drowsy in the first weeks; to stop diphenhydramine and avoid other sleep aids and allergy pills that cause drowsiness; to report muscle weakness, bone pain or unusual tiredness after the iron infusions, since these can reflect low phosphate; and not to stop pregabalin suddenly. He said he had hoped to take fewer pills, and he accepted the plan once he understood that pramipexole would eventually stop.
Review Date, Stopping Plan and What Would Change the Prescription
The first review is in four weeks, with telephone contact after the second infusion. Pregabalin is intended as long-term treatment if effective; if it is stopped, it will be tapered over at least one week. Four results would change the prescription: phosphate below 2.0 mg/dL after the infusions; no improvement on the rating scale after eight weeks at 300 mg of pregabalin, which would lead to a trial of gabapentin enacarbil if coverage can be obtained or a low-dose opioid; a sleep study showing obstructive sleep apnea, which would be treated and pregabalin dosing reconsidered; and worsening depression, which would prompt a joint review with his psychiatrist.
References
Garcia-Borreguero, D., Silber, M. H., Winkelman, J. W., Högl, B., Bainbridge, J., Buchfuhrer, M., Hadjigeorgiou, G., Inoue, Y., Manconi, M., Oertel, W., Ondo, W., Winkelmann, J., & Allen, R. P. (2016). Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: A combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Medicine, 21, 1-11. https://doi.org/10.1016/j.sleep.2016.01.017
Winkelman, J. W., Berkowski, J. A., DelRosso, L. M., Koo, B. B., Scharf, M. T., Sharon, D., Zak, R. S., Kazmi, U., Falck-Ytter, Y., Shelgikar, A. V., Trotti, L. M., & Walters, A. S. (2025). Treatment of restless legs syndrome and periodic limb movement disorder: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 21(1), 137-152. https://doi.org/10.5664/jcsm.11390
Wolf, M., Rubin, J., Achebe, M., Econs, M. J., Peacock, M., Imel, E. A., Thomsen, L. L., Carpenter, T. O., Weber, T., Brandenburg, V., & Zoller, H. (2020). Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: Two randomized clinical trials. JAMA, 323(5), 432-443. https://doi.org/10.1001/jama.2019.22450
What the NUR 635 Topic 8 instructions ask for
The benchmark for NUR-635 comes at Topic 8: a comprehensive prescribing case for one patient. Strong cases present the patient in full, set a therapeutic goal that can be measured and dated, and select each agent with the alternatives a competent colleague would have considered and why each was declined. Students should give dose, route, interval and duration for every agent, review interactions across the whole list, including over-the-counter products and alcohol, and match monitoring to the specific risks of each drug. The case should end with teaching the patient could follow, a review date and a stopping plan stating what would change the prescription. A goal written in the patient's terms, such as the hour symptoms begin, makes success easy to judge at review.
How the NUR-635 Topic 8 example is put together
The finished example defends a whole prescription rather than choosing a drug. Each element carries its own justification: why this agent over the obvious alternative, why this dose given the patient's clearance, why this route, why this duration, what is monitored and when. The alternatives are named and declined with reasons, which is what makes the choice a decision rather than a default. Everything the course established is used, kinetics for the dose, interaction review for the safety, special population adjustment where it applies, and risk weighing where the agent warrants it. The teaching is written out. The example ends with what would change the plan and when the patient is next reviewed.
Reading the NUR 635 Topic 8 rubric
Faculty reward a complete prescription with alternatives declined. An Excellent case sets a goal of onset after 9 p.m. within 16 weeks and recognizes augmentation from earlier onset and spread to the arms. Credit goes to tapering pramipexole, infusing ferric carboxymaltose and starting pregabalin, citing Garcia-Borreguero and colleagues and Winkelman and colleagues. The rubric values interactions with alcohol and diphenhydramine. Strong cases monitor phosphate after iron, with Wolf and colleagues. Top marks go to a review date and stated triggers for change.
Common NUR 635 Topic 8 mistakes, and how to avoid them
Cases that select a drug and stop are the failure this benchmark exposes, because the assignment asks for a complete prescribing decision and the drug is one part of six. A second weakness is elements justified collectively rather than individually, where one paragraph covers the choice and the dose, the route and the duration arrive unexamined. Papers lose marks for omitting the alternatives, since a choice with nothing rejected reads as the only option the writer knew. Monitoring without thresholds and teaching described rather than written are the two omissions that recur most. A prescription with no review date has not finished the decision it started. Cases that never state the patient's own preference treat a shared decision as a technical one.
Get an NUR-635 Topic 8 example written to your instructions
Send the NUR-635 Topic 8 instructions and the rubric from your classroom, with the case your section assigned and the patient's full medication list. We write a custom example to those criteria, with every element separately defended, alternatives named and declined, monitoring given thresholds and a review date fixed, in 24 to 48 hours. The first is free.
More NUR 635 papers and MSN samples
- NUR 635 Topic 1: Pharmacokinetics Application
- NUR 635 Topic 2: Antimicrobial Selection Rationale
- NUR 635 Topic 3: Cardiovascular Prescribing Analysis
- NUR 635 Topic 4: Respiratory Therapy Plan
- NUR 635 Topic 5: Apixaban Drug Selection Paper
- NUR 635 Topic 6: Risk Benefit Prescribing Analysis
- NUR 635 Topic 7: Special Population Dosing
- NUR 641EA Topic 8: Session Defended by Evidence
- NUR 634 Topic 8: Comprehensive Case Write-up
- NUR 643EA Topic 8: Single Skill Teaching Plan
- NUR 631 Topic 8: Integrated Case Analysis
NUR 635 Topic 8 questions, answered
What counts as a complete prescribing decision?
Agent, dose, route, frequency, duration, monitoring and patient teaching, each with a reason. Students routinely defend the first and treat the rest as consequences, but a correct drug at a wrong interval, or without the monitoring it requires, is not a safe prescription. Working through all seven, briefly, is more valuable than an extended argument about the choice of agent alone.
How many alternatives should I consider?
The one or two a competent colleague would have reached for, considered properly, rather than a survey of the class. Naming the obvious alternative and saying specifically why it was declined for this patient demonstrates that the choice was made rather than defaulted to. A long list of rejected options with a sentence each shows breadth where the rubric wanted judgment.
How much detail does the teaching section need?
Enough that somebody could deliver it. What the drug is for, how and when to take it, what to expect and by when, what would mean stopping and seeking review, and anything specific such as rinsing, food timing or avoiding another product. Writing that education was provided records that something happened without recording what, which is the version that loses the mark.
Where can I find a free NUR 635 Topic 8 sample paper?
The case for NUR 635 Topic 8 covers the patient in full, the therapeutic goal, agents with alternatives declined, dose and route, interactions and monitoring, teaching and the review date and stopping plan. Send the NUR 635 Topic 8 prompt from your course for a free paper.
Why give iron for restless legs in NUR 635 Topic 8?
Because low brain iron is linked to the condition, and guidelines support intravenous iron when ferritin or transferrin saturation is below set thresholds.